Company / Operating Cash Flow per Share
Cullinan Therapeutics, Inc. Operating Cash Flow per Share History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.48
FY2024
5-year range
-$3.23 / -$1.00
FY2020-FY2024
Trend
+23.2%
vs FY2023
Sector context
#157 of 212
Health Care
What the data says
At $-2.48, Cullinan Therapeutics, Inc.'s operating cash flow per share ranks #157 of 212 in the Health Care sector. Operating Cash Flow per Share returned to growth in FY2024 after 2 years of decline, reaching $-2.48.
Based on SEC 10-K filings.
-2.48 in FY2024.
Improved from $-2.77 to $-2.48 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#157 of 212 in Health CareTop 74% of 212This company -$2.48 Sector average -$14.73
▼
+83.1% above sector average
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 23.2% year-over-year.
- Ranks #157 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$2.48 | +23.2% |
| FY2023 | -$3.23 | -16.8% |
| FY2022 | -$2.77 | -177.1% |
| FY2021 | -$1.00 | +33.3% |
| FY2020 | -$1.50 | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026